Similar to what would be expected in cells expressing canonical CBRs, chronic exposure (48 h) of prostate cancer cells to the canonical CB1/CB2 full agonist WIN-55,212-2 (10 μM) produced pronounced downregulation in both PC-3 (Figure 6A) and DU-145 (Figure 6B) cells, reducing the amount of [3H]WIN-55,212-2 (1 nM) binding by 84.33 ± 5.2 and 88.45 ± 5.22%, respectively. Here, CNR1 is linked to prostate cancer.